Mark Tengler
Vorstandsvorsitzender bei Spectrix Therapeutics LLC
Profil
Mark T.
Tengler is the founder of Spectrix Therapeutics LLC, which is founded in 2016, where he holds the title of Chief Executive Officer.
He also held the position of Chief Technology Officer at Neos Therapeutics, Inc. from 2014 to 2016.
Prior to that, he worked as Operations Director at PharmaPrint, Inc. Mr. Tengler received his undergraduate degree from Colorado State University.
Aktive Positionen von Mark Tengler
| Unternehmen | Position | Beginn |
|---|---|---|
Spectrix Therapeutics LLC
 Spectrix Therapeutics LLC Pharmaceuticals: MajorHealth Technology Spectrix Therapeutics LLC is a privately held specialty pharmaceutical company. It provide and develops St-ME01, and ST-RHU02. The company was founded by Mark Tengler, John Q. Adams Jr., and John Dyett in 2016 and is headquartered in Southlake, TX. | Vorstandsvorsitzender | 01.01.2016 |
Ehemalige bekannte Positionen von Mark Tengler
| Unternehmen | Position | Ende |
|---|---|---|
| NEOS THERAPEUTICS, INC. | Präsident | - |
PharmaPrint, Inc.
 PharmaPrint, Inc. BiotechnologyHealth Technology PharmaPrint, Inc. develops dietary supplements, functional foods, and pharmaceutical products from botanical sources. The private company is based in Irvine, CA. | Geschäftsführer | - |
Ausbildung von Mark Tengler
| Colorado State University | Undergraduate Degree |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Private Unternehmen | 3 |
|---|---|
PharmaPrint, Inc.
PharmaPrint, Inc. BiotechnologyHealth Technology PharmaPrint, Inc. develops dietary supplements, functional foods, and pharmaceutical products from botanical sources. The private company is based in Irvine, CA. | Health Technology |
Neos Therapeutics, Inc.
 Neos Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Neos Therapeutics, Inc is a pharmaceutical company focused on developing, manufacturing and commercializing products utilizing its proprietary modified-release drug delivery technology platforms. Its products are Adzenys XR-ODT (amphetamine), Cotempla XR-ODT (methylphenidate), and Adzenys-ER (amphetamine) extended-release oral suspension, all for the treatment of ADHD, are the first three approved products using the Company's extended-release technology platform. The firm manufactures and markets its generic version of the branded product Tussionex, an extended-release oral suspension of hydrocodone and chlorpheniramine for the relief of cough and upper respiratory symptoms of a cold. The company was founded by Darlene R. Ryan on November 30, 1994 and is headquartered in Grand Prairie, TX. | Health Technology |
Spectrix Therapeutics LLC
Spectrix Therapeutics LLC Pharmaceuticals: MajorHealth Technology Spectrix Therapeutics LLC is a privately held specialty pharmaceutical company. It provide and develops St-ME01, and ST-RHU02. The company was founded by Mark Tengler, John Q. Adams Jr., and John Dyett in 2016 and is headquartered in Southlake, TX. | Health Technology |
